A Review of Niosomes as Novel Drug Delivery Systems
DOI:
https://doi.org/10.37285/ijpsn.2021.14.6.2Abstract
The aim of this review is to present the structure of niosome, benefits and drawbacks, fundamentals of niosome preparation and characterization as well as a description of their applications in drug delivery. This review will provide an overview on the increasing interest on niosomes in the field of drug delivery. Drug delivery systems are defined as formulations aiming for transportation of a drug to the desired area of action within the body. The basic component of drug delivery systems is an appropriate carrier that protects the drug from rapid degradation or clearance and thereby enhances drug concentration in target tissues. Drug targeting is a kind of phenomenon in which drug gets distributed in the body in such a manner that the drug interacts with the target tissue at a cellular or subcellular level to achieve a desired therapeutic response at a desire site without undesirable interactions at other sites. This can be achieved by modern methods of targeting the drug delivery system such as niosomes. Niosomes are the type of non-ionic surfactant vesicles, which are biodegradable, non-toxic, more stable and inexpensive, a new approach to liposomes. Their structure similar to liposome and hence they can represent alternative vesicular systems with respect to liposomes. The niosomes have the tendency to load different type of drugs.
Downloads
Metrics
Keywords:
Niosomes, Structure of niosomes, Preparation, Different types, Characterization, Applications
Downloads
Published
How to Cite
Issue
Section
References
Abdelkader H, Wu Z, Al-Kassas R, and Alany RG (2012). Niosomes and discomes for ocular delivery of naltrexone hydrochloride: morphological, rheological, spreading properties and photo-protective effects. Int J Pharm 433: 142–148.
Abdelkader SH, Ismail S, Kamal A, and Alany RG (2011). Design and evaluation of con-trolled-release niosomes and discomes for naltrexone hydrochloride ocular de- livery. J Pharm Sci 100: 1833–1846.
Adnan Azeem, Nilu Jain, Zeenat Iqbal, Farhan Jalees Ahmad, Mohammad Aqil, and Sushama Talegaonkar (2008). Feasibility of Proniosomes Based Transdermal Delivery of Frusemide. Formulation Optimization and Pharmacotechnical Evaluation. Pharma Dev and Tech 13(2): 155 – 163.
Allen TM (1998). Liposomal drug formulations: rationale for development and what we can expect for the future. Drugs 56: 747–56.
Bandyopadhyay P and Johnson M (2007). Fatty alcohols or fatty acids as niosomal hybrid carrier: effect on vesicle size, encapsulation efficiency and in vitro dye release. Coll Sur B: Biointerf 58(1): 68–71.
Bayindir ZS and Yuksel N (2010). Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharma Sci 99(4): 2049–2060.
Bayindir ZS, Beşikci A, and Yüksel N (2015). Paclitaxel-loaded niosomes for intravenous administration: pharmacokinetics and tissue distribution in rats. Turkish Jo Med Sci 45(6):1403–1412.
Biju SS, Talegaonkar S, Misra PR, and Khar RK (2006). Vesicular systems: An overview. Indian J Pharm Sci 68: 141-153.
Bini KB, Akhilesh D, Prabhakara P, and Jv K(2012). Development and characterization of non-ionic surfactant vesicles (niosomes) for oral delivery of lornoxicam. Int J D Dev Res 4(3): 147–154.
Biswal S, Murthy PN, Sahu J, Sahoo P, and Amir F (2008). Vesicles Of Non-Ionic Surfactants (Niosomes) And Drug Delivery Potential. Int J Pharma Sci Nano; 1(1).
Chandu VP, Arunachalam A, Jeganath S, Yamini K, Tharangini K, and Chaitanya G (2012). Niosomes: A Novel Drug Delivery System, International Journal of Novel Trends in Pharma Sci 2(1).
Chen X, Huang W, Wong BC, Yin L, Wong YF, and Xu M (2012). Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int J Nanomedicine 7: 1139–48.
Chen, Shuo, Hanning, Sara, Falconer, James, Locke, Michelle, Wen, and Jingyuan (2019). Recent advances in non-ionic surfactant vesicles (niosomes): Fabrication, characterization, pharma-ceutical and cosmetic applications. Eur J Pharma Biopharma 144: 18-39.
Devender Sharma, Aashiya Aara E. Ali, Jayshree R and Aate (2017). Niosomes as Novel Drug Delivery System: Review Article. Pharma Tutor 6(3):58-65.
Devender Sharma, Aashiya Aara E. Ali, Jayshree R and Aate (2017). Niosomes as Novel Drug Delivery System: Review Article. Pharma Tutor 6(3): 58-65.
Dwivedi C, Sahu R, Tiwari S, Satapathy T, and Roy A (2014). Role of liposome in novel drug delivery system. J D Del Thera 4(2): 116-129.
Elhissi A, Hidayat K, Phoenix DA, Mwesigwa E, Crean S, Ahmed W,Faheem A, and Taylor KM (2013). Air-jet and vibrating-mesh nebulization of niosomes generated using a particulate-based proniosome technology. Int J Pharm 444: 193–199.
Esposito S, and Carafa M (2014). Niosomes from 80s to present: the state of the art. Adv Colloid Interface Sci 205:187–206.
Gadhiya P, Shukla S, Modi D, and Bharadia P (2012). Niosomes In Targeted Drug Delivery A Review. Int J Pharma Res Scholar 1(2).
Gayatri Devi S, Venkatesh P, and Udupa N (2000). Niosomal sumatriptan succinate for nasal administration. Int J Pharm Sci 62: 479-81.
Gopalakrishnan S, and Chenthilnathan A (2012). Niosomes A Novel Drug Delivery Device. Res J Pharma Bio Chem 3(3):1090.
Gopinath D, Ravi D, Rao BR, Apte SS,Renuka D and Rambhau D(2004). Ascorbyl palmitate vesicles (Aspasomes): formation, characterization, and applications. Int J Pharm 2(71): 95–113.
Gupta R, Kumar S, Gupta N, and Anurag Kumar (2014). The New Advancement Nanotechnology: Proniosomes as A Promising And Potential Drug Carrier. Int J Res Dev Pharma Life Sci 3(6): 1258-1265.
Hunter CA, Dolan TF, Coombs GH, and Baillie AJ (1988). Vesicular Systems (Niosomes and Liposomes) For Delivery of Sodium Stibogluconate In Experimental Murine Visceral Leishmaniasis. J Pharm Pharmacol 40(3): 161-165.
Ijeoma F, Uchegbu, Suresh P, and Vyas (1998). Non-ionic surfactant-based vesicles (niosomes) in drug delivery. Int. J. Pharm 172: 33–70.
Imran M, Shah ML, and Ullah F (2016). Glycoside-based niosomal nanocarrier for enhanced in-vivo performance of Cefixime. Int J Pharma 505(1-2):122– 132.
Jaiswal P, Kesharwani S, Kesharwani R, and Patel D (2016). Ethosome: a new technology used as topical & transdermal delivery system. J D Del The 6(3):7-17.
Jiao J (2008). Polyoxyethylated nonionic surfactants and their appli- cations in topical ocular drug delivery. Adv D Del Rev 60(15):1663–1673.
Jindal K (2015). Niosomes as A Potential Carrier System: A Review. Int J Pharma Chem Bio Sci 5(4): 947-959.
Junyaprasert VB, Teeranachaideekul V, and Supaperm T (2008). Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes. Pharm Sci Tech 9(3) :851–859.
Kalra NG, Jeyabalan, Singh G, and Choudhary S (2016). Non-Ionic Surfactant Vesicles and Their Therapeutics Potentials. J Ino Pharma Bio Sci 3(2):193-201.
Karim KM, Mandal AS, Biswas N, Guha A, Chatterjee S, Behera M, and Kuotsu K (2010). Niosome: A Future of Targeted Drug Delivery Systems. J Adv Pharma Tech Res 1(4).
Karim Masud Kazi, Asim Sattwa Mandal, Nikhil Biswas, Arijit Guha, Sugata Chatterjee, Mamata Behera, and Ketousetuo Kuotsu (2010). Niosome: A future of targeted drug delivery systems. J Adv Pharm Technol Res 1(4): 374–380.
Karim Masud Kazi, Asim Sattwa Mandal, Nikhil Biswas, Arijit Guha, Sugata Chatterjee, Mamata Behera, and Ketousetuo Kuotsu (2010). Niosome: A future of targeted drug delivery systems. J Adv Pharm Technol Res 1(4): 374–380.
Katare OP (2017). Niosome-based hydrogel of resveratrol for topical applications: An effective therapy for pain related disorder(s). Biomed Pharmacother 88: 480–487.
Kaur Dhanvir and Kumar Sandeep (2018). Niosomes: present scenario and future aspects. J D Del Thera 8(5): 35-43.
Keservani RK, Sharma AK, and Ayaz MD (2011). Novel Drug Delivery System For The Vesicular Delivery of Drug By The Niosomes. Int J Res Cont Rel 1(1): 1-8.
Khandare JN, Madhavi G, and Tamhankar BM (1994). Niosomes Novel Drug Delivery System. The East Pharma 37: 61-64.
Khindri S, Aggarwal S, and Hari Kumar SL (2015). Role of Niosomes And Proniosomes For Enhancing Bioavailability of Drugs. J D Del Thera 5(1): 28- 33.
Li Q, Li Z, and Zeng W (2014). Proniosome-derived niosomes for tacrolimus topical ocular delivery: in vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection. Eur J Pharma Sci 62: 115–123.
Liu T, Guo R, Hua W, and Qiu J(2007). Structure behaviors of hemoglobin inPEG6000/Tween 80/Span 80/H2O niosome system. Colloids and Surfaces A: Physico Eng Aspects 293(1–3): 255–261.
Mahale NB, Thakkar PD, Mali RG, Walunj DR, and Chaudhari SR (2012). Niosomes: novel sustained release nonionic stable vesicular systems an overview. Adv Col Inter Sci 183: 46–54.
Malhotra M and Jain N.K (1994). Niosomes as Drug Carriers. Indian D 31(3): 81-866.
Manconi M, Sinico C, Valenti D, Loy G, and Fadda AM (2003). Niosomes as carriers for tretinoin: II. Influence ofvesic- ular incorporation on tretinoin photostability. Int J Pharma 260(2): 261–272.
Manosroi A, Chankhampan C, Manosroi W, and Manosroi J (2013). Transdermal absorption enhancement of papain loaded in elastic niosomes incorporated in gel for scar treatment. Eur J PharmSci 48: 474–483.
Manosroi W, Manosroi J, Manosroi A, Ruksiriwanich W, Abe M, and Sakai H(2010). Biological activities of the rice bran extract and physical characteristics of its entrapment in niosomes by supercritical carbon dioxide fluid. J Supercrit Fluid 54: 137–144.
Manosroia A, Jantrawuta P, Manosroia J (2008). Anti-inflammatory activity of gel containing novel elastic niosomes entrapped with diclofenac diethylammonium. Int J Pharm 360: 156–163.
Marianecci C, Di Marzio L, and Rinaldi R (2014). Niosomes from 80s to present: the state of the art. Adv Col Inter Sci 205:187–206.
Marianecci C, Rinaldi F, and Mastriota M (2012). Anti-inflammatory activity of novel ammonium glycyrrhizinate/niosomes delivery system: human and murine models. J Cont Rel 164(1): 17–25.
Mayer LD, Bally MB, Hope MJ, and Cullis PR (1985).Uptake of Antineoplastic Agents Into Large Unilamellar Vesicles In Response To A Membrane Potential. Biochem Biophys Acta 816(2): 294-302.
Mishra, Vijay, Nayak, Pallavi, Singh, Manvendra, Sriram, Pavani, Suttee, and Ashish (2021). Niosomes: Potential nanocarriers for drug delivery. Int J Pharma Qua Ass 11(3): 389-394.
Moghassemi S and Hadjizadeh A (2014). Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Cont Re l85(1): 22–36.
Moghassemi, Saeid, Hadjizadeh, and Afra (2014). Nano-niosomes as nanoscale drug delivery systems: An illustrated review. J Cont Rel 185: 22–36.
Mokhtara M, Sammourb OA, Hammada MA, and Megrab NA (2017). Effect of some for- mulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm 361: 104–111.
Muzzalupo R, Tavano L, Cassano R, Trombino S, Ferrarelli T, and Picci N (2011). A new approach for the evaluation of niosomes as effective transdermal drug delivery systems. Eur J PharmaBiopharma 79(1): 28–35.
Nasir A, Harikumar SL, and Kaur A 2012. Niosomes: An Excellent Tool for Drug Delivery. Int J Res Pharma Chem 2(2).
Nasseri B (2005). Effect of cholesterol and temperature on the elastic properties of niosomal membranes. Int J Pharma 300(1-2): 95–101.
Negia P, Aggarwala M, Sharmab G, Rathorea C, Sharmac G, Singhb B and Katare OP (2017). Niosome-based hydrogel of resveratrol for topical applications: An effective therapy for pain related disorder(s). Biomed Pharmacother 88: 480–487.
Paolino D, Cosco D, Muzzalupo R, Trapasso E, Picci N, and Fresta M (2008). Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharma 353(1- 2): 233–242.
Paolino D, Muzzalupo R, Ricciardi A, Celia C, Picci N, and Fresta M (2007). In vitro and in vivo evaluation of Bola-surfactant containing niosomes for transdermal delivery. Biomed Micdevs 9(4): 421-33.
Pardakhty A, Varshosaz J, and Rouholamini A (2007). In vitro study of poly oxy ethylene alkyl ether niosomes for delivery of insulin. Int J Pharma 328(2): 130– 141.
Patel SM, Rathod DR, Patel KN, Patel BA, and Patel PA (2012). Niosome As an Effective Drug Delivery: A Review. Int J Pharma Res Sch 1(2).
Pei Ling Yeo, Chooi Ling Lim, Soi Moi Chye, Anna Pick Kiong Ling, and Rhun Yian Koh (2017). Niosomes: A Review of Their Structure, Properties, Methods Of Preparation, And Medical Applications. Asian Biomed 11(4): 301–14.
Rastogi B, Nagaich U, and Jain D (2014). Development and characterization of non-ionic surfactant vesicles for ophthalmic drug delivery of diclofenac potassium. J D Del Thera :1-6.
Reddy DN and Udupa N (1993). Formulation and Evaluation of Oral and Transdermal Preparation of Flurbiprofen and Piroxicam Incorporated with Different Carriers. Drug Dev Ind Pharm: 843.
Reddy DN and Udupa N (1993). Formulation and Evaluation of Oral and Transdermal Preparation of Flurbiprofen and Piroxicam Incorporated with Different Carriers. Drug Dev Ind Pharm 843.
Rogerson A, Cummings J, Willmott N and Florence AT (1988). The distribution of doxorubicin in mice following administration in niosomes. J Pharm Pharmacol 40: 337-342.
S. K. Mehta and N. Jindal, “Tyloxapol niosomes as prospective drug delivery module for antiretroviral drug nevirapine,” AAPS PharmSciTech, 16(1): pp. 67–75, 2014.
Saini N, Sodhi RK, Bajaj L,Pandey RS, Jain UK, Katare OP, and Madan J (2016).Intravaginal administration of metformin hydrochloride loaded cationic niosomes amalgamated with thermosensitive gel for the treatment of polycystic ovary syn-drome: In vitro and in vivo studies. Col Surf B 144:161–169.
Sankhyan A and Pawar P (2012). Recent trends in niosome as vesicular drug delivery system. J App Pharma Sci 2(6):20–32.
Sarker A, Shimu IJ, and Alam SAA (2015). Niosome: As Dermal Drug Delivery Tool, IOSR. J Pharma Bio Sci 10(2):73-79.
Schreier H, and Bouwstra J (1994). Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Con Rel 30(1):1-15.
Seleci M, Ag Seleci D, Joncyzk R, Stahl F, Blume C, and Scheper T (2016). Smart multifunctional nanoparticles in nanomedicine. Bio Nano Materials 17(1-2): 33–41.
Shahiwala A and Misra A (2002). Studies in topical application of niosomally entrapped nimesulide. J Pharma and Pharma Sci 5(3): 220–225.
Sharma BS, Bhogale V, Adepu AR, Patil ST, and Sangha SK (2015). Proniosomes : A Novel Provesicular Drug Delivery System. Int J Pharma Res Scholar 4(2): 40.
Singh S (2013). Niosomes: A Role in Targeted Drug Delivery System. Int J Pharma Sci Res 4(2): 550-557.
Srivastava NS, Thakur S, and Kaur J (2016). Niosomes: A Novel Approach for Topical Delivery of Drugs. Int J Pharma Tech 8(2): 11712-11731.
Sternberg B, Uchegbu IF, Florence AT and Murdan S (1998). Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85). J Pharma 7: 123-128.
Tangri P, and Khurana S (2011). Niosomes: Formulation and Evaluation. Int J Biopharma 2(1): 47-53.
Tavano L, Gentile L, Oliviero Rossi C, and Muzzalupo R (2013). Novel gel-niosomes formulations as multicomponent systems for transdermal drug delivery. Col Sur B: Biointer 110: 281–288.
Uchegbu IF and Florence AT (1995). Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Col Interface Sci 58(1): 1–55.
Uchegbu IF and S. P. Vyas SP (1998). Non-ionic surfactant-based vesicles (niosomes) in drug delivery. Int J Pharma 172(1-2): 33–70.
Verma NK and Roshan A (2014). Niosomes and its Application-A Review. Int J Res Pharma Life Sci 2(1): 182-184.
Vyas SP, Singh RP, and Jain S (2005). Non-ionic surfactant-based vesicles (niosomes) for non-invasive topical genetic immuniza- tion against hepatitis B. Int J Pharma 296(1-2): 80–86.
Weissman G, Bloomgarden D, Kaplan R, Cohen C, Hoffstein S, and Collins T (1975). A general method for the introduction of enzymes, by means of immunoglobulin-coated liposomes into lysosomes of deficient cells. Proc Natl Acad Sci 72: 88-92.
Yoshida H, Lehr CM, Kok W, Junginger HE, Verhoef JC, and Bouwstra JA (992). Niosomes for Oral Delivery of Peptide Drugs. J Cont Rel 21(1–3): 145-153.
Yoshioka T, Sternberg B, and Florence AT (1994). Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85). Int J Pharma 105(1): 1–6.
Yuksel N, Bayindir ZS, Aksakal E, and Ozcelikay AT (2016). In situ niosome forming maltodextrin proniosomes of candesartan cilexetil: In vitro and in vivo evaluations. Int J Biol Macromol 82: 453–463.
